Abstract 622P
Background
The modified mCCS intends to predict overall survival (OS) of mCRC patients (pts) at start of 1L therapy. Five clinical routine parameters assign pts into three prognostic risk groups from low to intermediate and high risk: tumor stage, tumor grading, lymph node ratio, primary tumor resection status and number of metastatic sites at start of 1L treatment (Marschner N, et al. Colorectal Dis. 2019). VALIDATE (NCT03043950) prospectively validates the mCCS in a large patient cohort with RAS WT mCRC.
Methods
VALIDATE is a multicenter, non-interventional study evaluating real-world effectiveness, safety and quality of life in pts with RAS WT mCRC receiving 1L PAN plus FOLFIRI/FOLFOX. Pts were allocated to three mCCS risk groups. This second interim analysis (IA2) was performed 24 months after last patient in. Data were analyzed descriptively for effectiveness, response rates and secondary resection rates.
Results
At data-base cut (Nov 17, 2022), 611 pts from 108 German and 5 Austrian sites were evaluable. Median age was 66.1 years, 68.9% of pts were male and 83.3% had an ECOG performance status 0/1. 59.4% of pts were diagnosed with a colon tumor. 84.3% of these pts had a left-sided tumor.
Table: 622P
Total N=611 | mCCS | |||
Low risk N=202 | Intermediate risk N=198 | High risk N=211 | ||
Overall response rate n (%) | 381 (62.4%) | 121 (59.9%) | 128 (64.6%) | 132 (62.6%) |
Secondary resections n (%) | 115 (18.8%) | 43 (21.3%) | 47 (23.7%) | 25 (11.8%) |
24-month OS rate [95%-CI] | 54.2% [50.0, 58.3] | 60.0% [52.4, 66.8] | 61.3% [53.8, 67.9] | 42.3% [35.3, 49.0] |
Most common grade 3/4 (MedDRA v20.0) treatment-emergent adverse drug reactions (TEADR) were dermatitis acneiform (5.8%), rash (2.9%) and diarrhea (3.2%). One investigator assessed fatal TEADR (arterial embolism) occurred.
Conclusions
The IA2 showed favorable effectiveness for PAN plus FOLFIRI/FOLFOX in the total population and in all mCCS risk groups in clinical routine in Germany and Austria. Interestingly, rates of secondary resections were >20% for low and intermediate risk pts. mCCS predicting OS will be validated in the final analysis. No new safety signals emerged.
Clinical trial identification
NCT03043950.
Editorial acknowledgement
Legal entity responsible for the study
iOMEDICO AG.
Funding
Amgen.
Disclosure
M. Reiser: Financial Interests, Institutional, Principal Investigator: iOMEDICO/VALIDATE. J. Uhlig: Financial Interests, Personal and Institutional, Advisory Board: Roche, Amgen, Servier, MSD, Bristol Myers Squibb, Sanofi, Merck, Celgene, Novartis, Janssen-Cilag, Boehringer Ingelheim, Bayer, BeiGene; Financial Interests, Institutional, Principal Investigator: iOMEDICO/VALIDATE. L. Jacobasch, L. Mueller: Financial Interests, Institutional, Principal Investigator: iOMEDICO/VALIDATE. A. Schuch, L. Serrer, R. de Buhr: Financial Interests, Personal, Full or part-time Employment: iOMEDICO. H.U. Siebenbach: Financial Interests, Personal, Full or part-time Employment: iOMEDICO. T. Göhler: Financial Interests, Institutional, Principal Investigator: iOMEDICO/VALIDATE. J.K. Schröder: Financial Interests, Personal and Institutional, Advisory Board: Celgene, Roche, Bristol Myers Squibb, Clovis Oncology, GSK, Boehringer Ingelheim, Amgen, Novartis, MSD, AOP, Searchlight, Pharma Partner, Medicline, Eisai, HE Research, Octapharma, AbbVie, NIO, I+E Pharma, ISPEN, BeiGene, Milteny; Financial Interests, Institutional, Principal Investigator: iOMEDICO/VALIDATE. D. Semsek: Financial Interests, Institutional, Principal Investigator: iOMEDICO/VALIDATE. A. Koehler: Financial Interests, Institutional, Principal Investigator: iOMEDICO/VALIDATE; Financial Interests, Personal, Advisory Board: Roche, Novartis, Pfizer, Amge, Daiichi Sankyo MSD. P. Stübs: Non-Financial Interests, Institutional, Principal Investigator: iOMEDICO/VALIDATE. K.M. Potthoff: Financial Interests, Personal, Full or part-time Employment: iOMEDICO. N.W. Marschner: Non-Financial Interests, Personal and Institutional, Invited Speaker: Amgen, BeiGene, Roche, GSK, Euspharm, stemline, Seagen, Servier; Non-Financial Interests, Personal and Institutional, Advisory Board: Amgen, AstraZeneca, BeiGene, , Bristol Myers Squibb, Celgene, Daiichi Sankyo, Deciphera, Eisai, Eusapharm, Gilead, GSK, Janssen, Lilly, Mundipharma, Merck, Mylan, MSD, Novartis, Oncopeptides, Oncovis, Pfizer, Pierre Fabre, Roche, Seagen, Servier Stemline; Financial Interests, Personal and Institutional, Member of Board of Directors: iOMEDICO; Financial Interests, Personal and Institutional, Full or part-time Employment: iOMEDICO; Financial Interests, Institutional, Ownership Interest: iOMEDICO; Non-Financial Interests, Institutional, Research Grant: Amgen, AstraZeneca, BeiGene, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Deciphera, Eisai, Eusapharm, Gilead, GSK, Janssen, Lilly, Mundipharma, Merck, Mylan, MSD, Novartis, Oncopeptides, Oncovis, Pfizer, Pierre Fabre, Roche, Seagen, Servier, Stemline; Non-Financial Interests, Institutional, Funding: Amgen, AstraZeneca, BeiGene, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Deciphera, Eisai, Eusapharm, Gilead, GSK, Janssen, Lilly, Mundipharma, Merck, Mylan, MSD, Novartis, Oncopeptides, Oncovis, Pfizer, Pierre Fabre, Roche, Seagen, Servier, Stemline; Financial Interests, Personal, Project Lead: iOMEDICO/VALIDATE.
Resources from the same session
570P - Subclasses of microsatellite-instability colorectal cancer with unique molecular features and immune cell infiltration patterns
Presenter: Kui Wu
Session: Poster session 10
571P - Artificial intelligence-powered analysis of tumor lymphocytes infiltration: A translational analysis of AtezoTRIBE trial
Presenter: Martina Carullo
Session: Poster session 10
572P - Neoantigen heterogeneity among subtypes in colorectal cancer
Presenter: Fuqiang Li
Session: Poster session 10
574P - Comparative analysis of the tumor immune microenvironment (TIME) in primary and metastatic sites of microsatellite stable (MSS) and microsatellite instability-high (MSI) colorectal cancer
Presenter: Marwan Fakih
Session: Poster session 10
575P - Impact of immunological alterations and post-operative biomarkers on long-term outcomes in patients with locally advanced rectal cancer: Results from the STAR-01 study cohort
Presenter: Francesca Negri
Session: Poster session 10
576P - Prognostic values of a modified diagnostic biopsy-adapted immunoscore based on double immunohistochemical staining in patients with locally advanced rectal cancer
Presenter: Qiang Zeng
Session: Poster session 10
577P - Systematically assessing the intratissue microbiota in 937 patients with colorectal cancer
Presenter: Huanzi Zhong
Session: Poster session 10
578P - Tissue-resident microbiota characterization in colorectal cancer metastases
Presenter: Philippe Stevens
Session: Poster session 10
579P - A clinico-imaging predictive artificial intelligence model of relapse in colon cancer using baseline CT scans
Presenter: América Bueno Gómez
Session: Poster session 10